ECVTEcovyst Inc.
Chemicals & Allied Products
- Revenue
- $724M
- 21% YoY
- Operating margin
- 9.0%
- 37% YoY
- EBITDA
- $133M
- 24% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- 3.1×
- $405M net debt
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCClear1% of revenueOver 10% of revenue
- Payouts exceed cash flowClear33% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear28% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $611M | $820M | $585M | $598M | $724M | 21% |
| Operating income | $55M | $104M | $90M | $85M | $65M | 24% |
| Net income | $2M | $70M | $71M | −$7M | −$71M | 961% |
| Operating cash flow | $130M | $187M | $138M | $150M | $140M | 6.4% |
| Capex | $60M | $59M | $59M | $56M | $70M | 27% |
| Stock-based comp | $32M | $21M | $13M | $11M | $10M | 12% |
| Buybacks | $0 | $137M | $79M | $5M | $47M | 837% |
| Dividends | $436M | $0 | $0 | — | — |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $250K · 1
- Open-market sells, 12 mo
- $0 · 0
- Net
- $250K
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | — | — | 84 | 103 |
| FY2024 | — | — | 66 | 105 |
| FY2023 | — | — | 85 | 108 |
| FY2022 | — | — | 77 | 97 |
| FY2021 | — | — | 89 | 117 |